These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436 [TBL] [Abstract][Full Text] [Related]
16. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study. Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies. Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538 [TBL] [Abstract][Full Text] [Related]
18. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW; JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836 [TBL] [Abstract][Full Text] [Related]
19. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial. Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027 [TBL] [Abstract][Full Text] [Related]
20. Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial). Katagiri Y; Onuma Y; Asano T; Iñiguez A; Jensen LO; Cequier À; Hofma SH; Christiansen EH; Suttorp M; Brugaletta S; Räber L; Sabaté M; Windecker S; Serruys PW EuroIntervention; 2018 Dec; 14(11):e1224-e1226. PubMed ID: 30398967 [No Abstract] [Full Text] [Related] [Next] [New Search]